你所需,我所有_肿瘤液体活检方案有Thermo Fisher就够%.pptxVIP

The world leader in serving science Proprietary Confidential 你所需，我所有 ——肿瘤液体活检方案有Thermo Fisher就够了 For Research Use Only. Not for use in diagnostic procedures 2 ©2016 Thermo Fisher Scientific Corporation. All rights reserved. Molecular testing guidelines for informing treatment options for NSCLC patients, as recommended by CAP1, AMP1, IASLC1, and NCCN2: EGFR, ALK, ROS1, BRAF, and PDL1 testing for first-line therapies2 Emerging targeted agents for patients with other genetic alterations, including KRAS, HER2, MET, and RET2 Broader molecular profiling to identify rare driver mutations for which effective drugs may be already available, or to appropriately counsel patients regarding the availability of clinical trials; broad molecular profiling is a key component of the improvement to care of patients with NSCLC2 多基因检测为相关指南所推荐 精准治疗方案的制定离不开多基因检测，多种相关指南均建议实体肿瘤患者可尝试多基因检测。 Journal of Molecular Diagnostics, Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors. Guideline from the College of American Pathologists, International Association for the Study of L ung Cancer, and Association for Molecular Pathology 15(4), July 2013. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™), Non-Small Cell Lung Cancer, v8.2017, NCCN.org. For in vitro diagnostic use. 实时的肿瘤分子分型有助于选择最为合适的治疗策略 Therapy 1 Therapy 2 Therapy 3 EGFR Exon 19 EGFR Exon 19 (20%) EGFR Exon 19 (29%) EGFR Exon 19 (20%) KRAS p.G13D (55%) T790M (6%) T790M (2%) MET p.N375S (40%) P53 p.G245V (10%) P53 p.G245V (3%) MET p.T1010I (20%) MET p.N375S (59%) MET p.N375S (55%) Baseline Time 1 TBB/TTB Time 2 Pleuraerguss (90%) Time 3 Liquid biopsy (ctDNA) EGFR (Exon 19) 肿瘤分子分型的时空特异性 治疗压力可能会导致肿瘤发Th变异，产Th耐药突变或者驱动基因的改变 3 ©2016 Thermo Fisher Scientific Corporation. All rights reserved. For Research Use Only. Not for use in diagnostic procedures 液体活检可作为组织活检的有效补充 液体活检 非侵入性的实时取样：为需要实时监控疗效 的靶向治疗患者提供耐药监测的可能 取样容易：为无手术样本或难以穿刺的肿瘤 患者提供精准靶向治疗方案的可能 4 ©2016 Thermo Fisher Scien